SCHEMBL633176

SCHEMBL633176

CC1CCC2(CC1)C(=O)OC2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.40
CYP3A4 P08684 4/20 0.40
TP53 P04637 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP1A2 P05177 3/20 0.40
HIF1A Q16665 2/20 0.40
LMNA P02545 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NFKB1 P19838 1/20 0.40
THPO P40225 1/20 0.40
PPM1B O75688 1/20 0.40
PTPN1 P18031 1/20 0.40
PPP1CC P36873 1/20 0.40
TFPI2 P48307 1/20 0.40
PPP5C P53041 1/20 0.40
PPP2CA P67775 1/20 0.40
PPP1CA P62136 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GMNN O75496 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19628663 0.77 CRBN (0.36) CYP3A4SMN1; SMN2CYP1A2LMNARAB9A
SCHEMBL2344957 0.76
SCHEMBL13880044 0.74 TNKS (0.41) MAPK1SMN1; SMN2LMNARAB9ANFKB1
SCHEMBL632818 0.74 CYP1A2 (0.38) MAPK1CYP3A4TP53SMN1; SMN2CYP1A2
SCHEMBL8173778 0.71 LMNA (0.38) MAPK1CYP3A4TP53SMN1; SMN2CYP1A2
SCHEMBL6525946 0.71 TP53 (0.32) MAPK1CYP3A4TP53SMN1; SMN2CYP1A2
SCHEMBL430025 0.71
SCHEMBL6377360 0.71 MAPK1 (0.32) MAPK1CYP3A4TP53SMN1; SMN2CYP1A2
SCHEMBL8920960 0.70 CYP1A2 (0.44) MAPK1CYP3A4TP53SMN1; SMN2CYP1A2
SCHEMBL8174280 0.70 ALDH1A1 (0.44) TP53SMN1; SMN2CYP1A2HIF1ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12091506-B2 Highly soluble tris-(2, 3-epoxypropyl)-isocyanurate and method for producing same NISSAN CHEMICAL CORPORATION (JP) 2024-09-17 US claimed
US-20090163652-A1 THERMOSETTING RESIN COMPOSITION AND USE THEREOF CHISSO CORPORATION (JP) 2009-06-25 US claimed
US-12305004-B2 Cationically polymerizable composition JNC CORPORATION (JP) 2025-05-20 US disclosed
US-12091506-B2 Highly soluble tris-(2, 3-epoxypropyl)-isocyanurate and method for producing same NISSAN CHEMICAL CORPORATION (JP) 2024-09-17 US disclosed
US-12077636-B2 Highly soluble tris-(2,3-epoxypropyl)-isocyanurate and method for producing same NISSAN CHEMICAL CORPORATION (JP) 2024-09-03 US disclosed
US-20240240059-A1 EPOXY RESIN MODIFIER, EPOXY RESIN COMPOSITION CONTAINING SAME, ADHESIVE COMPOSED OF EPOXY RESIN COMPOSITION, AND RESIN CURED PRODUCT OBTAINED BY CURING EPOXY RESIN COMPOSITION OTSUKA CHEMICAL CO., LTD. (JP) 2024-07-18 US disclosed
CN-114933725-B Super capacitor with carbon fiber/epoxy resin-based structure and preparation method thereof 上海墨浦科技有限公司 2024-01-26 CN disclosed
US-20230287179-A1 HIGHLY SOLUBLE TRIS-(2,3-EPOXYPROPYL)-ISOCYANURATE AND METHOD FOR PRODUCING SAME NISSAN CHEMICAL CORPORATION (JP) 2023-09-14 US disclosed
WO-2023276702-A1 EPOXY RESIN MODIFIER, EPOXY RESIN COMPOSITION CONTAINING SAME, ADHESIVE COMPOSED OF EPOXY RESIN COMPOSITION, AND RESIN CURED PRODUCT OBTAINED BY CURING EPOXY RESIN COMPOSITION 大塚化学株式会社 2023-01-05 WO disclosed
CN-109991810-B Highly soluble tris- (2, 3-epoxypropyl) -isocyanurate and process for producing the same 日产化学工业株式会社 2022-11-11 CN disclosed
CN-114933725-A Carbon fiber/epoxy resin-based structure super capacitor and preparation method thereof 上海墨浦科技有限公司 2022-08-23 CN disclosed
US-20120052296-A1 GLASS FIBER-SILSESQUIOXANE COMPOSITE MOLDED ARTICLE AND METHOD FOR PRODUCING SAME JNC CORPORATION (JP) 2012-03-01 US disclosed
EP-2420529-A1 GLASS FIBER-SILSESQUIOXANE COMPOSITE MOLDED ARTICLE AND METHOD FOR PRODUCING SAME JNC Corporation (JP) 2012-02-22 EP disclosed
US-20100273937-A1 ORGANOSILICON COMPOUND AND THERMOSETTING RESIN COMPOSITION CONTAINING THE SAME CHISSO CORPORATION (JP) 2010-10-28 US disclosed
US-20100267980-A1 CURING ACCELERATOR FOR DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN, DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN COMPOSITION, AND DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN CURED PRODUCT NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) 2010-10-21 US disclosed
US-20090163652-A1 THERMOSETTING RESIN COMPOSITION AND USE THEREOF CHISSO CORPORATION (JP) 2009-06-25 US disclosed
US-20090118442-A1 CURING ACCELERATOR FOR DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN, DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN COMPOSITION, AND DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN CURED PRODUCT NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) 2009-05-07 US disclosed
CN-1142960-C Resin system ABB��ʿ���޹�˾ 2004-03-24 CN disclosed
US-6468659-B1 TWO COMPONENTS WHICH CAN BE STORED SEPARATELY AND CROSSLINKED WITH ANOTHER AT ROOM TEMPERATURE; A GLYCIDYLAMINE COMPOUND AND AN ANHYDRIDE;PREFERABLY WITHOUT USING A CURING ACCELERATOR. ABB SCHWEIZ AG (CH) 2002-10-22 US disclosed
CN-1313872-A Resin system ABB CORPORATE RES LTD (CH) 2001-09-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267980-A1 CURING ACCELERATOR FOR DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN, DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN COMPOSITION, AND DEEP-ULTRAVIOLET-TRANSMITTING EPOXY RESIN CURED PRODUCT ELL, RAD54L, RPP30 MAPK1 2282/4885CYP3A4 3162/4885TP53 3998/4885
US-20100273937-A1 ORGANOSILICON COMPOUND AND THERMOSETTING RESIN COMPOSITION CONTAINING THE SAME OR51E2, STS, OXER1 MAPK1 3123/4885CYP3A4 1007/4885TP53 3925/4885
US-20230287179-A1 HIGHLY SOLUBLE TRIS-(2,3-EPOXYPROPYL)-ISOCYANURATE AND METHOD FOR PRODUCING SAME TTPA, USP1, USP2 MAPK1 2526/4885CYP3A4 1157/4885TP53 3775/4885
US-12077636-B2 Highly soluble tris-(2,3-epoxypropyl)-isocyanurate and method for producing same TTPA, USP1, USP2 MAPK1 2526/4885CYP3A4 1157/4885TP53 3775/4885
US-12091506-B2 Highly soluble tris-(2, 3-epoxypropyl)-isocyanurate and method for producing same TTPA, USP1, USP2 MAPK1 2526/4885CYP3A4 1157/4885TP53 3775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.